Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY1082439 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BAY1082439 | DRUG | BAY1082439 will be given orally once daily with a 21 days cycle. Dose will be started from 15mg. |
Inclusion Criteria: * Subjects with advanced, histologically or cytologically confirmed solid tumors, refractory to any standard therapy, have no standard therapy available, or subjects must have actively refused any treatment which would be regarded standard, and / or if in the judgment of the inv...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
BAY1082439 is an investigational small molecule developed by Bayer AG for the treatment of neoplasms, or advanced cancers. It is a Phase 1 oncology candidate and has not been approved for any indication. Bayer AG trades over the counter under the ticker BAYRY.
BAY1082439 is being studied for use in patients with neoplasms, meaning advanced or solid cancers. Its only recorded clinical study enrolled adults with advanced cancer. The drug remains investigational and is not approved for treating cancer or any other condition.
BAY1082439 targets PIK3CA and PIK3CB, two isoforms of phosphoinositide 3-kinase. It is classified as an inhibitor of these targets, which are part of the PI3K signaling pathway frequently altered in cancer. Targeting both isoforms distinguishes it from agents selective for a single PI3K isoform.
BAY1082439 is developed by Bayer AG, the German pharmaceutical and life sciences company. Bayer's ordinary shares trade on the Frankfurt exchange, and its American depositary receipts trade over the counter in the United States under the ticker BAYRY.
BAY1082439 is in Phase 1 clinical development. Its single recorded trial was an open label Phase 1 study in patients with advanced cancer, and that study is now completed. The drug is investigational and has not received FDA approval.
BAY1082439 has been evaluated in one clinical trial, NCT01728311, titled an open label study of BAY1082439 in patients with advanced cancer. That Phase 1 trial enrolled 60 patients across Singapore, South Korea, and Taiwan and is completed. No active trials are currently recorded.